CD24/Siglec-10 Blocking Peptide (CSBP) contains a sequence engineered to disrupt CD24-Siglec-10 binding interfaces. Charged and aromatic residues provide targeted recognition of protein surfaces. Researchers study its binding kinetics, conformational dynamics, and specificity. Applications include receptor-ligand mapping, PPI inhibition modeling, and structural-motif exploration.
CAT No: R2842
Synonyms/Alias:CD24/Siglec-10 blocking peptide, CSBP; HY-P10091; CS-0906803
CD24/Siglec-10 blocking peptide, also known as CSBP, is a specialized carbohydrate-based compound designed to interfere with the interaction between CD24 and Siglec-10, two key molecular players involved in immune regulation. As a synthetic peptide mimetic, CSBP is engineered to selectively disrupt the CD24-Siglec-10 axis, a pathway that has garnered significant attention in immunological research due to its role in modulating immune cell responses and mediating immune evasion. The unique structure of this blocking peptide allows it to bind specifically to Siglec-10 or the CD24 ligand, thereby preventing their natural engagement and subsequent signal transduction. Researchers value CSBP for its high specificity, stability in experimental conditions, and compatibility with various in vitro and in vivo systems, making it a versatile tool for dissecting complex immune pathways and advancing the understanding of immune checkpoint mechanisms.
Immunology research: In immunology research, CD24/Siglec-10 blocking peptide serves as a critical reagent for unraveling the molecular mechanisms underlying immune cell regulation. By blocking the interaction between CD24 and Siglec-10, investigators can precisely evaluate the downstream effects on immune cell activation, cytokine production, and phagocytic activity. This carbohydrate compound is particularly useful for studies exploring the modulation of innate and adaptive immune responses, providing insights into how immune cells distinguish between self and non-self signals. Through its targeted mechanism, CSBP enables researchers to dissect the contributions of the CD24-Siglec-10 axis in immune tolerance, inflammation, and autoimmunity, supporting the development of novel immunotherapeutic strategies.
Cancer biology studies: In the field of cancer biology, CSBP is employed to investigate the mechanisms by which tumor cells exploit the CD24-Siglec-10 pathway to evade immune surveillance. Tumor-associated overexpression of CD24 can engage Siglec-10 on macrophages, leading to the suppression of anti-tumor immune responses. By introducing the blocking peptide into experimental models, researchers can disrupt this inhibitory signal, enabling a clearer understanding of the role of immune checkpoints in tumor progression and metastasis. The use of CSBP in these studies facilitates the identification of potential targets for cancer immunotherapy and aids in the characterization of the tumor microenvironment.
Cell signaling pathway analysis: CSBP is instrumental in cell signaling studies aimed at delineating the downstream effects of CD24-Siglec-10 interaction. By preventing the natural ligand-receptor engagement, scientists can assess changes in intracellular signaling cascades, such as those involving phosphatases, kinases, and transcription factors. This application is essential for mapping the networks that govern immune cell fate decisions and for identifying key molecular nodes that may be targeted for therapeutic intervention. The ability of CSBP to selectively block this pathway makes it a valuable probe for uncovering novel signaling mechanisms and regulatory checkpoints.
Inflammation and autoimmune disease models: In experimental models of inflammation and autoimmune diseases, the blocking peptide is used to study the role of the CD24-Siglec-10 axis in controlling excessive immune activation. By inhibiting this pathway, researchers can evaluate the impact on inflammatory mediator release, tissue infiltration by immune cells, and the resolution of inflammatory responses. These studies provide important data on how the modulation of CD24-Siglec-10 interaction influences disease outcomes, supporting the exploration of new approaches for managing chronic inflammatory and autoimmune conditions.
Neuroimmunology investigations: CSBP is also gaining traction in neuroimmunology research, where the CD24-Siglec-10 pathway is implicated in neuroinflammation and neurodegenerative processes. By blocking the interaction in neural tissue models, scientists can probe its effects on microglial activation, neuronal survival, and the balance between neuroprotection and neurotoxicity. This application sheds light on the intricate crosstalk between the immune system and the nervous system, offering opportunities to investigate the molecular underpinnings of neurological disorders and to identify innovative targets for intervention. With its broad utility across diverse research domains, CD24/Siglec-10 blocking peptide continues to drive discoveries in immune regulation, disease mechanisms, and therapeutic development.
1. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
3. Emu oil in combination with other active ingredients for treating skin imperfections
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More